{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:47:21Z","timestamp":1794329241848,"version":"4.9.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:00:00Z","timestamp":1675468800000},"content-version":"am","delay-in-days":368,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007659","name":"Bayer Corp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2UL1TR001425-05A1"],"award-info":[{"award-number":["2UL1TR001425-05A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009109","name":"Pharmaceuticals Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007150","name":"United Therapeutics Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.chest.2021.07.2162","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T04:47:26Z","timestamp":1628052446000},"page":"448-457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Riociguat for Sarcoidosis-Associated Pulmonary Hypertension"],"prefix":"10.1016","volume":"161","author":[{"given":"Robert P.","family":"Baughman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana A.","family":"Shlobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse E.","family":"Lower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck F.","family":"Rahaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Zeigler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chest.2021.07.2162_bib1","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1378\/chest.09-2002","article-title":"Survival in sarcoidosis associated pulmonary hypertension: the importance of hemodynamic evaluation","volume":"138","author":"Baughman","year":"2010","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2021.07.2162_bib2","doi-asserted-by":"crossref","first-page":"1901747","DOI":"10.1183\/13993003.01747-2019","article-title":"Survival of patients with sarcoidosis associated pulmonary hypertension: the impact of baseline hemodynamics, pulmonary function, and six minute walk test in a multi-national registry cohort","volume":"55","author":"Shlobin","year":"2020","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.chest.2021.07.2162_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00465-2017","article-title":"Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension","volume":"50","author":"Boucly","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2021.07.2162_bib4","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1378\/chest.08-1881","article-title":"Treatment of sarcoidosis-associated pulmonary hypertension: a two-center experience","volume":"135","author":"Barnett","year":"2009","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2021.07.2162_bib5","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1378\/chest.14-2546","article-title":"Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: a retrospective case series","volume":"148","author":"Bonham","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.chest.2021.07.2162_bib6","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1378\/chest.13-1766","article-title":"Bosentan for sarcoidosis associated pulmonary hypertension: a double-blind placebo controlled randomized trial","volume":"145","author":"Baughman","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.chest.2021.07.2162_bib7","first-page":"110","article-title":"Inhaled iloprost for sarcoidosis associated pulmonary hypertension","volume":"26","author":"Baughman","year":"2009","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"2","key":"10.1016\/j.chest.2021.07.2162_bib8","first-page":"139","article-title":"Ambrisentan for sarcoidosis associated pulmonary hypertension","volume":"28","author":"Judson","year":"2011","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"1","key":"10.1016\/j.chest.2021.07.2162_bib9","doi-asserted-by":"crossref","first-page":"1801908","DOI":"10.1183\/13993003.01908-2018","article-title":"Clinical trial design and new therapies for pulmonary arterial hypertension","volume":"53","author":"Sitbon","year":"2019","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.chest.2021.07.2162_bib10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.chest.2021.07.2162_bib11","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.chest.2021.07.2162_bib12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.chest.2021.07.2162_bib13","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S2213-2600(19)30250-4","article-title":"Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study","volume":"7","author":"Nathan","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"Sep","key":"10.1016\/j.chest.2021.07.2162_bib14","first-page":"149","article-title":"ATS\/ERS\/WASOG statement on sarcoidosis. American Thoracic Society\/European Respiratory Society\/World Association of Sarcoidosis and other Granulomatous Disorders","volume":"16","author":"Hunninghake","year":"1999","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.chest.2021.07.2162_bib15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.rmed.2018.04.015","article-title":"Clinical features of sarcoidosis associated pulmonary hypertension: results of a multi-national registry","volume":"139","author":"Baughman","year":"2018","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.chest.2021.07.2162_bib16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00392-014-0765-4","article-title":"Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options","volume":"104","author":"Rosenkranz","year":"2015","journal-title":"Clin Res Cardiol"},{"issue":"6","key":"10.1016\/j.chest.2021.07.2162_bib17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.healun.2021.02.006","article-title":"Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: a post hoc subgroup analysis of the RISE-IIP study","volume":"40","author":"Nathan","year":"2021","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"1","key":"10.1016\/j.chest.2021.07.2162_bib18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","article-title":"Spirometric reference values from a sample of the general U.S. population","volume":"159","author":"Hankinson","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2021.07.2162_bib19","first-page":"185","article-title":"Standardized single breath normal values for carbon monoxide diffusing capacity","volume":"123","author":"Crapo","year":"1981","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"10.1016\/j.chest.2021.07.2162_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1378\/chest.06-2822","article-title":"Six-minute walk test and health status assessment in sarcoidosis","volume":"132","author":"Baughman","year":"2007","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2021.07.2162_bib21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00005650-199303000-00006","article-title":"The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs","volume":"31","author":"McHorney","year":"1993","journal-title":"Med Care"},{"issue":"1","key":"10.1016\/j.chest.2021.07.2162_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/thoraxjnl-2012-201962","article-title":"The development and validation of the King\u2019s Sarcoidosis Questionnaire for the assessment of health status","volume":"68","author":"Patel","year":"2013","journal-title":"Thorax"},{"issue":"pt 3","key":"10.1016\/j.chest.2021.07.2162_bib23","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1348\/1359107041557048","article-title":"Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS)","volume":"9","author":"de Vries","year":"2004","journal-title":"Br J Health Psychol"},{"issue":"1","key":"10.1016\/j.chest.2021.07.2162_bib50","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1371\/journal.pmed.0050020","article-title":"CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration","volume":"5","author":"Hopewell","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.chest.2021.07.2162_bib49","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/bmj.2.5261.1165","article-title":"Prognosis of intrathoracic sarcoidosis in England","volume":"4","author":"Scadding","year":"1961","journal-title":"Br Med J"},{"issue":"1 suppl","key":"10.1016\/j.chest.2021.07.2162_bib24","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.jacc.2009.04.007","article-title":"End points and clinical trial design in pulmonary arterial hypertension","volume":"54","author":"McLaughlin","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"suppl 1","key":"10.1016\/j.chest.2021.07.2162_bib25","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/01.mcp.0000370206.61003.7e","article-title":"Clinical worsening in trials of pulmonary arterial hypertension: results and implications","volume":"16","author":"Galie","year":"2010","journal-title":"Curr Opin Pulm Med"},{"issue":"2","key":"10.1016\/j.chest.2021.07.2162_bib26","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1183\/09031936.05.00054804","article-title":"Survival with first-line bosentan in patients with primary pulmonary hypertension","volume":"25","author":"McLaughlin","year":"2005","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2021.07.2162_bib27","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.healun.2007.11.576","article-title":"Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil?","volume":"27","author":"Milman","year":"2008","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"2","key":"10.1016\/j.chest.2021.07.2162_bib28","first-page":"82","article-title":"Treatment of sarcoidosis-associated pulmonary hypertension: a single centre retrospective experience using targeted therapies","volume":"31","author":"Keir","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"9","key":"10.1016\/j.chest.2021.07.2162_bib29","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Galie","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.chest.2021.07.2162_bib30","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2021.07.2162_bib31","first-page":"90","article-title":"Endpoints for clinical trials of sarcoidosis","volume":"29","author":"Baughman","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"3","key":"10.1016\/j.chest.2021.07.2162_bib32","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1161\/CIRCULATIONAHA.112.105890","article-title":"Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials","volume":"126","author":"Gabler","year":"2012","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.chest.2021.07.2162_bib33","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.drudis.2014.04.020","article-title":"Endpoints in PAH clinical trials in the era of combination therapy: how do we decide whether something is working without going bankrupt?","volume":"19","author":"McGlinchey","year":"2014","journal-title":"Drug Discov Today"},{"issue":"22","key":"10.1016\/j.chest.2021.07.2162_bib34","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A\u00a0phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.chest.2021.07.2162_bib35","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(16)30019-4","article-title":"Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial","volume":"4","author":"Ghofrani","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.chest.2021.07.2162_bib36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1183\/09031936.00038709","article-title":"Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome","volume":"35","author":"Cottin","year":"2010","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2021.07.2162_bib37","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1378\/chest.08-2306","article-title":"Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension","volume":"136","author":"Mejia","year":"2009","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2021.07.2162_bib38","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1378\/chest.15-0615","article-title":"Histopathology of explanted lungs from patients with a diagnosis of pulmonary sarcoidosis","volume":"149","author":"Zhang","year":"2016","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.chest.2021.07.2162_bib39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00330-004-2480-4","article-title":"CT findings in severe thoracic sarcoidosis","volume":"15","author":"Hennebicque","year":"2005","journal-title":"Eur Radiol"},{"issue":"12","key":"10.1016\/j.chest.2021.07.2162_bib40","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1164\/rccm.200402-249OC","article-title":"A\u00a0case control etiologic study of sarcoidosis: environmental and occupational risk factors","volume":"170","author":"Newman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.chest.2021.07.2162_bib41","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-158-9-201305070-00003","article-title":"Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial","volume":"158","author":"Raghu","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.chest.2021.07.2162_bib42","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1513\/AnnalsATS.202006-607OC","article-title":"Evaluating the minimal clinically important difference of the King\u2019s Sarcoidosis Questionnaire (KSQ) in a multi-center, prospective study","volume":"18","author":"Baughman","year":"2020","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"10.1016\/j.chest.2021.07.2162_bib43","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00408-020-00394-7","article-title":"The St. George\u2019s Respiratory Questionnaire in pulmonary sarcoidosis","volume":"198","author":"Lo","year":"2020","journal-title":"Lung"},{"issue":"9","key":"10.1016\/j.chest.2021.07.2162_bib44","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.rmed.2011.05.004","article-title":"Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis","volume":"105","author":"de Kleijn","year":"2011","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.chest.2021.07.2162_bib45","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00408-017-9994-4","article-title":"Repository corticotropin for chronic pulmonary sarcoidosis","volume":"195","author":"Baughman","year":"2017","journal-title":"Lung"},{"issue":"1","key":"10.1016\/j.chest.2021.07.2162_bib46","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.chest.2016.08.1473","article-title":"Macitentan improves health-related quality of life for patients with pulmonary arterial hypertension: results from the randomized controlled SERAPHIN trial","volume":"151","author":"Mehta","year":"2017","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.chest.2021.07.2162_bib47","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12931-016-0388-6","article-title":"Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT\u00ae) questionnaire: a new patient-reported outcome instrument for PAH","volume":"17","author":"McCollister","year":"2016","journal-title":"Respir Res"},{"issue":"5","key":"10.1016\/j.chest.2021.07.2162_bib48","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1513\/pats.200802-020SK","article-title":"Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension","volume":"5","author":"Chen","year":"2008","journal-title":"Proc Am Thorac Soc"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369221036138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369221036138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T23:02:41Z","timestamp":1762124561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369221036138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0012369221036138"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2021.07.2162","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Riociguat for Sarcoidosis-Associated Pulmonary Hypertension","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2021.07.2162","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}